| Bioactivity | Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research[1][2]. |
| Invitro | MOR202 介导的对多发性骨髓瘤 (MM) 细胞系的毒性作用可以被蛋白酶体抑制剂硼替佐米 (BOR) 和免疫调节剂来那度胺 (LEN) 增强[1]。 |
| In Vivo | 在鼠 MM 模型中，MOR202 可以剂量依赖性的减少骨溶解，在 12 mg/kg 时高达 55%。而在低剂量 3 mg/kg 时 与 0.6 mg/kg BOR 或 50 mg/kg LEN 的共同给药可完全消除了骨溶解[1]。 |
| Name | Felzartamab |
| CAS | 2197112-39-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. J. Endell, et al. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.Meeting Abstract | 2011 ASCO Annual Meeting I [2]. Marc S Raab, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020 May;7(5):e381-e394. |